Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program; ACE1831 is an allogeneic gamma delta T cell therapy candidate targetin ...

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase ...

Artificial intelligence (AI) is transforming the pharmaceutical industry, revolutionising drug discovery and approval processes, and reshaping how researchers identify potential drug candidates ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

The field of cancer therapeutics has seen significant advancements with the development and FDA approval of drugs targeting ...